DK0830604T3 - Anvendelser af apoptin - Google Patents

Anvendelser af apoptin

Info

Publication number
DK0830604T3
DK0830604T3 DK96916378T DK96916378T DK0830604T3 DK 0830604 T3 DK0830604 T3 DK 0830604T3 DK 96916378 T DK96916378 T DK 96916378T DK 96916378 T DK96916378 T DK 96916378T DK 0830604 T3 DK0830604 T3 DK 0830604T3
Authority
DK
Denmark
Prior art keywords
apoptin
apoptosis
normal cells
tumor
cells
Prior art date
Application number
DK96916378T
Other languages
English (en)
Inventor
Matheus Hubertus Mari Noteborn
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/484,939 external-priority patent/US6319693B1/en
Application filed by Leadd Bv filed Critical Leadd Bv
Application granted granted Critical
Publication of DK0830604T3 publication Critical patent/DK0830604T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Light Receiving Elements (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK96916378T 1995-06-07 1996-06-07 Anvendelser af apoptin DK0830604T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/484,939 US6319693B1 (en) 1990-09-12 1995-06-07 Cloning of chicken anemia virus DNA
PCT/NL1996/000229 WO1996041191A1 (en) 1995-06-07 1996-06-07 Methods and uses for apoptin

Publications (1)

Publication Number Publication Date
DK0830604T3 true DK0830604T3 (da) 2003-09-29

Family

ID=23926260

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96916378T DK0830604T3 (da) 1995-06-07 1996-06-07 Anvendelser af apoptin

Country Status (11)

Country Link
EP (1) EP0830604B1 (da)
JP (1) JPH11506340A (da)
AT (1) ATE241808T1 (da)
AU (1) AU718422B2 (da)
CA (1) CA2221495C (da)
DE (1) DE69628431T2 (da)
DK (1) DK0830604T3 (da)
ES (1) ES2200065T3 (da)
NZ (1) NZ309171A (da)
PT (1) PT830604E (da)
WO (1) WO1996041191A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188832A1 (en) * 2000-09-08 2002-03-20 Leadd B.V. A delivery method for the tumor specific apoptosis inducing activity of apoptin
CA2301401C (en) * 1997-08-12 2008-10-21 Leadd B.V. Determining the transforming capability of agents
AU2004233486B2 (en) * 1999-01-11 2007-09-13 Leadd B.V. Use of apoptosis inducing agents in the treatment of (auto)immune diseases
EA200100770A1 (ru) * 1999-01-11 2002-02-28 Леадд Б.В. Применение агентов, индуцирующих апоптоз, в лечении (ауто)имунных заболеваний
PT1083224E (pt) * 1999-09-02 2007-03-30 Leadd Bv Proteína associada a apoptina
JP2003516152A (ja) * 1999-12-10 2003-05-13 レアト ベー．フェー． アポプチン会合タンパク質
WO2002020809A1 (en) * 2000-09-08 2002-03-14 Leadd B.V. A delivery method for the tumor specific apoptosis inducing activity of apoptin
EP1186665A1 (en) * 2000-09-08 2002-03-13 Leadd B.V. A delivery method for the tumor specific apoptosis inducing activity of apoptin
EP1199363A1 (en) * 2000-10-20 2002-04-24 Leadd B.V. Phosphorylation modifications of apoptin
DE60229924D1 (de) * 2001-03-30 2009-01-02 Leadd Bv Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
AU2002259005A1 (en) * 2001-04-24 2002-11-05 Washington University Compositions and methods for inducing cancer cell death
WO2003089936A1 (en) * 2002-04-19 2003-10-30 Leadd B.V. Aberrant-specific pathways
AU2003214721A1 (en) * 2002-04-19 2003-11-03 Leadd B.V. Fragments of apoptin
EP2643343A1 (en) 2010-11-26 2013-10-02 Institut Pasteur Identification of a human gyrovirus and applications.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9301272A (nl) * 1993-07-20 1995-02-16 Aesculaap Bv Chicken Anemia Virus mutanten en vaccins en toepassingen gebaseerd op de virale eiwitten VP1, VP2 en VP3 of daarvoor coderende sequenties van dat virus.
US5981502A (en) * 1990-09-12 1999-11-09 Leadd B.V. Methods and compositions for inducing apoptosis in tumor cells

Also Published As

Publication number Publication date
AU5913696A (en) 1996-12-30
CA2221495C (en) 2010-06-01
WO1996041191A1 (en) 1996-12-19
AU718422B2 (en) 2000-04-13
ES2200065T3 (es) 2004-03-01
PT830604E (pt) 2003-10-31
EP0830604B1 (en) 2003-05-28
DE69628431T2 (de) 2004-05-06
ATE241808T1 (de) 2003-06-15
JPH11506340A (ja) 1999-06-08
CA2221495A1 (en) 1996-12-19
EP0830604A1 (en) 1998-03-25
DE69628431D1 (de) 2003-07-03
NZ309171A (en) 2000-04-28

Similar Documents

Publication Publication Date Title
Naito et al. TRAF6-deficient mice display hypohidrotic ectodermal dysplasia
DE69628431D1 (de) Verwendungen von apoptin
MX9709913A (es) Metaloconstrucciones determinadas estructuralmente y aplicaciones.
Sause et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer
DE69233399D1 (de) Menschliches cyclin e
DK0961780T3 (da) Proteinmarkörer for lungecancer og anvendelse deraf
DE69231245D1 (de) Veraendertes gen bei menschlichem colorektalem-krebs
Shin et al. Mechanism of the antitumor and radiosensitizing effects of a manganese porphyrin, MnHex-2-PyP
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2001091805A3 (en) Compounds for targeting endothelial cells
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
EP1004022A4 (en) METHODS AND COMPOSITIONS TO OVERCOME RESISTANCE TO BIO- AND CHEMOTHERAPY
WO2003016499A3 (en) Combinatorial methods for inducing cancer cell death
Park et al. p21WAF1 is required for interleukin-16-induced migration and invasion of vascular smooth muscle cells via the p38MAPK/Sp-1/MMP-9 pathway
Fukai et al. Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase
MX9706107A (es) Moldes para paneles prefabricados de hormigon.
DE60032784D1 (de) Markerproteine für prostatakrebs
PL346246A1 (en) Modulating multiple lineage kinase proteins
DK1185279T3 (da) Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1
WO2000018961A3 (en) Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
Sanchez et al. In vitro study of the stress response of human skin cells to GSM-1800 mobile phone signals compared to UVB radiation and heat shock
Guthrie Dynamic compartmentalization of DNA repair proteins within spiral ganglion neurons in response to noise stress
Ansari et al. Effects of 60 Hz extremely low frequency magnetic fields (EMF) on radiation-and chemical-induced mutagenesis in mammalian cells
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
MX9709860A (es) Metodos y usos para la apoptina.